Tumor Microenvironment and Treatment in Uveal Melanoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 3944
Special Issue Editor
Special Issue Information
Dear Colleagues,
Although a relatively rare disease, primary uveal melanoma (UM) is the most common malignant tumor of the eye in adults, with a yearly incidence of 5.1 cases per million. Primary UMs are effectively treated by resection, radiation therapy, or enucleation; however, more than 50% of UM patients ultimately succumb to metastases, specifically metastases of the liver.
Tebentafusp (KIMMTRAKR), a gp-100-trageting TCR/anti-CD3 bispecific fusion protein, is FDA-approved for treatment of metastatic uveal melanoma with HLA-A*02:01– positive. The fusion protein activates antitumor immune responses in patients’ tumor microenvironment.
Understanding the dynamic interactions between cancer cells and their microenvironment is crucial for a better grasp on the mechanisms of cancer, including how it grows, metastasizes, and resists treatment. These assessments will contribute to the development of efficient and safe therapeutic strategies to improve patient outcomes as well as disrupt cancer cells directly and indirectly.
In this Special Issue, original research articles and reviews are welcome. Papers may cover areas such as the biology of UM, its microenvironment, and treatment options, highlighting both basic and clinical aspects.
I look forward to receiving your contributions.
Dr. Mizue Terai
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- uveal melanoma
- metastatic uveal melanoma
- tumor microenvironment
- pre-clinical research models
- immunotherapies
- targeted therapies
- liver-directed therapies
